Clinical improvement of DM1 patients reflected by reversal of disease-induced gene expression in blood

, , Remco T.P. van Cruchten, Daniël van As, Jeffrey C. Glennon, Baziel G.M. van Engelen, Peter A.C. ‘t Hoen

Research output: Contribution to journalArticlepeer-review

1 Citation (Scopus)
57 Downloads (Pure)


Background: Myotonic dystrophy type 1 (DM1) is an incurable multisystem disease caused by a CTG-repeat expansion in the DM1 protein kinase (DMPK) gene. The OPTIMISTIC clinical trial demonstrated positive and heterogenous effects of cognitive behavioral therapy (CBT) on the capacity for activity and social participations in DM1 patients. Through a process of reverse engineering, this study aims to identify druggable molecular biomarkers associated with the clinical improvement in the OPTIMISTIC cohort. 

Methods: Based on full blood samples collected during OPTIMISTIC, we performed paired mRNA sequencing for 27 patients before and after the CBT intervention. Linear mixed effect models were used to identify biomarkers associated with the disease-causing CTG expansion and the mean clinical improvement across all clinical outcome measures. 

Results: We identified 608 genes for which their expression was significantly associated with the CTG-repeat expansion, as well as 1176 genes significantly associated with the average clinical response towards the intervention. Remarkably, all 97 genes associated with both returned to more normal levels in patients who benefited the most from CBT. This main finding has been replicated based on an external dataset of mRNA data of DM1 patients and controls, singling these genes out as candidate biomarkers for therapy response. Among these candidate genes were DNAJB12, HDAC5, and TRIM8, each belonging to a protein family that is being studied in the context of neurological disorders or muscular dystrophies. Across the different gene sets, gene pathway enrichment analysis revealed disease-relevant impaired signaling in, among others, insulin-, metabolism-, and immune-related pathways. Furthermore, evidence for shared dysregulations with another neuromuscular disease, Duchenne muscular dystrophy, was found, suggesting a partial overlap in blood-based gene dysregulation. 

Conclusions: DM1-relevant disease signatures can be identified on a molecular level in peripheral blood, opening new avenues for drug discovery and therapy efficacy assessments.

Original languageEnglish
Article number395
Number of pages17
JournalBMC Medicine
Issue number1
Early online date10 Nov 2022
Publication statusPublished - 2022


  • Biomarker
  • Lifestyle intervention
  • Myotonic dystrophy type 1
  • Peripheral blood
  • RNA-seq
  • Therapeutic Response

ASJC Scopus subject areas

  • General Medicine


Dive into the research topics of 'Clinical improvement of DM1 patients reflected by reversal of disease-induced gene expression in blood'. Together they form a unique fingerprint.

Cite this